A latest clinical study published in the *New England Journal of Medicine* demonstrates breakthrough progress in the treatment of non-small cell lung cancer and melanoma using immune checkpoint inhibitors combined with targeted drugs. Data show that the median progression-free survival in the combination therapy group reached 15.2 months, nearly doubling the 8.1 months observed in the monotherapy group. The objective response rate (ORR) increased from 35% in the monotherapy group to 62%, with a disease control rate as high as 85%. These findings come from a Phase III randomized controlled trial involving 1,200 patients across 12 countries worldwide.
The study specifically focused on patients who had developed resistance after first-line treatment. In patients with EGFR mutation-positive non-small cell lung cancer, the combination regimen (PD-1 inhibitor plus third-generation EGFR-TKI) achieved a median overall survival of 28.6 months, compared to only 16.4 months in the traditional chemotherapy group. Meanwhile, the incidence of adverse events was comparable to the monotherapy group, with grade 3 or higher adverse events occurring at a rate of 22%, and no unexpected additive toxicity was observed.
Background and Significance
Immunotherapy and targeted therapy are two pillars of cancer treatment in recent years. Immunotherapy works by activating the patient's own immune system to attack tumors, while targeted drugs precisely act on specific genetic mutation sites. It was previously believed that the mechanisms of the two might interfere with each other, but this study found that in specific subtypes, their combination can produce synergistic effects. For example, in ALK fusion gene-positive lung cancer, the combination of a PD-1 inhibitor with a second-generation ALK inhibitor increased T-cell infiltration in the tumor microenvironment by threefold, providing mechanistic evidence for the rationale of the combination regimen.
Furthermore, the study explored biomarker-guided individualized combination strategies. For patients with PD-L1 expression ≥50%, the advantage of combination therapy was even more pronounced, with progression-free survival extended to 18.9 months. This suggests that precise patient selection can maximize the benefits of combination therapy while avoiding unnecessary toxicity.
Significance for International Patients
For international patients, these new data mean more treatment options. Especially for those with refractory tumors that have progressed on traditional treatment regimens, the combination approach offers new hope. However, the applicability of combination therapy depends on genetic testing results and immune microenvironment assessment, which requires medical institutions to have comprehensive molecular pathology testing capabilities and multidisciplinary collaboration teams.
Currently, this combination regimen has been included in the recommended lists of the U.S. NCCN guidelines and the European ESMO guidelines, but it has not yet received regulatory approval in all countries. Therefore, patients may face accessibility issues. For example, certain targeted drugs may not yet be available in specific countries, or insurance coverage may be limited. International patients often need to seek cross-border medical resources to gain access to the latest therapies.
How MedBridge Shanghai Can Help
MedBridge Shanghai, as a cross-border medical platform, can assist international patients in connecting with multiple partner hospitals in Shanghai that offer this combination therapy. We provide the following specific services:
1. **Genetic Testing Coordination**: Collaborating with top domestic pathology laboratories to complete comprehensive genetic testing (including NGS and PD-L1 expression analysis), with a report turnaround time shortened to 7 working days.
2. **Treatment Plan Matching**: Based on test results and the patient's treatment history, a multidisciplinary team (MDT) evaluates the suitability of combination therapy and develops an individualized plan.
3. **Transparent Cost Estimation**: Through our cost estimator tool, patients can learn the total treatment costs in advance (including medications, hospitalization, testing, etc.), avoiding hidden expenses.
4. **Medication Follow-up Management**: Adverse event monitoring and dose adjustments during treatment are managed through a remote follow-up system to ensure patient safety.
We have helped cancer patients from over 20 countries complete combination therapy. If you or your loved ones would like more information about immunotherapy combined with targeted therapy, please feel free to contact us or browse our medical services page.
Related reading: Overview of Partner Hospitals in Shanghai